![]() ![]() The website of the FCA can be accessed at Foresight Group LLP is a limited liability partnership incorporated in England and Wales (registered number 0C300878). Foresight Group LLPįoresight Group LLP is authorised and regulated by the Financial Conduct Authority ("FCA”). If you do not accept these Terms and Conditions please do not continue to access this Site. By accessing any part of this Site, you will be deemed to have accepted these Terms and Conditions in full. The information contained on these website pages (this "Site") is communicated and issued by Foresight Group LLP and Foresight Group CI Limited (details below) in accordance with the following terms and conditions. Please Scroll Down to Accept These Terms About Us These Terms and Conditions were last revised in July 2017. Please read this important information before accessing the website. Investors should only invest in Foresight EIS funds on the basis of information contained in the Foresight Williams Technology EIS Fund Information Memorandum dated October 2018 and Key Information Document.įoresight Group LLP is authorised and regulated by the Financial Conduct Authority (FRN: 198020). ![]() We recommend investors seek advice from a regulated financial adviser. Foresight Group LLP does not provide advice and the information on this website should not be construed as such. Past performance is not a reliable indicator of future performance. EIS should be considered a longer-term investment, which may be higher risk and more difficult to realise than listed securities. Tax reliefs are dependent on investee companies maintaining EIS qualifying status and investors’ individual circumstances. Eis group full#The value of an investment, and any income from it, can fall as well as rise and investors may not get back the full amount they invest. Eis group trial#This study, the largest reported trial of any CIDP treatment, shows the short-term and long-term efficacy and safety of IGIV-C and supports use of IGIV-C as a therapy for CIDP.Capital is at risk. The most common adverse events with IGIV-C were headache, pyrexia, and hypertension. The incidence of serious adverse events per infusion was 0.8% (9/1096) with IGIV-C versus 1.9% (11/575) with placebo. During the extension phase, participants who continued to receive IGIV-C had a longer time to relapse than did patients treated with placebo (p=0.011). Results were similar during the crossover period. Improvements from baseline to endpoint were also recorded for grip strength in the dominant hand (treatment difference 10.9 kPa, 4.6-17.2 p=0.0008) and the non-dominant hand (8.6 kPa, 2.6-14.6 p=0.005). ![]() This trial is registered with, number NCT00220740.ĭuring the first period, 32 of 59 (54%) patients treated with IGIV-C and 12 of 58 (21%) patients who received placebo had an improvement in adjusted INCAT disability score that was maintained through to week 24 (treatment difference 33.5%, 95% CI 15.4-51.7 p=0.0002). ![]() Patients who showed an improvement and completed 24 weeks of treatment were eligible to be randomly re-assigned in a blinded 24-week extension phase. The primary outcome was the percentage of patients who had maintained an improvement from baseline in adjusted INCAT disability score of 1 point or more through to week 24. IGIV-C (Gamunex) or placebo was given every 3 weeks for up to 24 weeks in an initial treatment period, and patients who did not show an improvement in INCAT disability score of 1 point or more received the alternate treatment in a crossover period. We aimed to establish whether 10% caprylate-chromatography purified immune globulin intravenous (IGIV-C) has short-term and long-term benefit in patients with CIDP.ġ17 patients with CIDP who met specific neurophysiological inflammatory neuropathy cause and treatment (INCAT) criteria participated in a randomised, double-blind, placebo-controlled, response-conditional crossover trial. Short-term studies suggest that intravenous immunoglobulin might reduce disability caused by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) but long-term effects have not been shown. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |